Navigation Links
MiMedx Group Announces 2010 Results
Date:3/28/2011

products and services may not gain the anticipated acceptance in the marketplace or that acceptance may be delayed, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2009. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws. MIMEDX GROUP, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS Year EndedNine Months EndedDecember 31,December 31,20102009REVENUES:Net sales$
544,155$
800Grant Revenue244,719-Total revenue788,874800OPERATING COSTS AND EXPENSES:Cost of products sold1,720,066240Research and development expenses

2,753,3312,590,227Selling, General and Administrative expenses

6,848,1353,463,303Gain on sale of assets-(280,868)LOSS FROM OPERATIONS(10,532,658)(5,772,102)OTHER INCOME (EXPENSE)Financing expense associated with issuance of common stock for registration rights waivers

-(1,305,100)Financing expense associated with warrants issuedin connection with convertible promissory note

(287,449)(975,833)Interest (expense) income, net(599,649)(242,634)LOSS BEFORE INCOME TAXES(11,419,756)(8,295,669)Income taxes--NET LOSS(11,419,756)(8,295,669)Net loss per common shareBasic and diluted$
(0.19)$
(0.20)Shares used in computing net loss per common shareBasic and diluted59,138,35741,365,513See notes to consolidated financial statementsMIMEDX GROUP, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETSASSETSDecember 31,20102009Current assets:Cash and cash equivalents$
,340,922$
2,653,537Accounts receivable, net162,376-Inventory111,55430,920Prepaid expenses and other current assets

90,946121,277Total current assets1,705,7982,805,734Property and equipment, ne
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. MiMedx Group Announces Temporary Trading Symbol Designation
2. MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference
3. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
4. MiMedx Group, Inc. to Present at the 13th Annual Needham Growth Conference
5. MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
6. MiMedx Announces Launch of AmnioFix™
7. MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
8. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
9. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
10. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
11. KJT Group Positions for Substantial Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015   Senomyx , Inc. (NASDAQ: SNMX ... to discover, develop, and commercialize novel flavor ingredients for ... financial results for the second quarter 2015. ... remain on track to achieve our commercial and financial ... of the Company. "Since our last quarterly earnings report, ...
(Date:7/30/2015)... Denmark , July 30, 2015 ... biotechnology company that applies its innovative TransCon technology ... positive top-line results from a six-month Phase 2 ... once-weekly TransCon Growth Hormone in 53 treatment-naïve, pre-pubertal ... "We are extremely pleased with the top-line ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, Inc. ... has received the second $1.0M tranche under a ... (SBIR) grant valued at up to $3.0 million ... KL4 surfactant as a potential medical countermeasure to ... Labs was awarded an initial $1.0 million under ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's Pony™ NS2006L ... operation up to 1500 bar. The sanitary design gauge of the NS2006L is ... , The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... Jacobs Engineering,Group Inc. (NYSE: JEC ) announced ... (BSE: GDRB) to provide engineering, procurement, and,construction management ... research & development and,manufacturing facility in Debrecen, Hungary., ... noted they would,execute the work from their office ...
... OR AKIVA, Israel, September 30 ITGI Medical,Ltd. ... and marketing of heterologous tissue covered stents,announced that ... CE Mark approval., AneuGraft(R) is a stent ... a barrier between the coronary blood vessel wall ...
... Calif., Sept. 30 Genomic,Health, Inc. (Nasdaq: ... President and Chief Operating Officer, will present at ... on Tuesday, October 7,2008 at 10:00 a.m. ET., ... webcast of the,presentation, visit the Investor Relations section ...
Cached Biology Technology:Jacobs Receives Contract From Gedeon Richter for New Biotechnology Facility in Hungary 2ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels 2
(Date:7/21/2015)... OXFORD, Connecticut , July 21, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet, announces that it has ... Tokenization System and Method. This ... that not only authorizes an account, but also ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:7/8/2015)... , N.J. and NEW YORK , July ... Guidepoint today announced BD & Guidepoint ... companies with free access to Guidepoint,s expert network services. ... that are developing cutting-edge technologies to improve healthcare delivery ... Guidepoint research manager, each start-up entrepreneur will be able ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... Noiri and colleagues at the University of Tokyo, Japan identified ... present their data in the April 2009 issue of The ... kidney injury may be reversible if treated promptly and appropriately. ... at early time points as well as to estimate the ...
... Australia,s most endangered snake might mean lighting more bush ... of broad-headed snakes are being threatened by encroaching woodland ... from the University of Sydney and Stanford University (USA) ... in small pockets within 200 km of Sydney, and ...
... Red jasper cored from layers 3.46 billion years old suggests ... but that the atmosphere was as oxygen rich as it ... chert formed in ways similar to the way this rock ... "Many people have assumed that the hematite in ancient ...
Cached Biology News:Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 5Australia's most endangered snake might need burning 2Deep-sea rocks point to early oxygen on Earth 2
Porcine Aortic Smooth Muscle Cells (PAOSMC) (>500,000 cells)...
... IV Recognizes an epitope located ... β-tubulin isotype IV. No reactivity ... observed. ascites fluid synthetic peptide ... of β-tubulin isotype IV, conjugated ...
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
Porcine Aortic Endothelial Cells (PAOEC) (>500,000 cells)...
Biology Products: